roche_dark_0

Roche’s Tecentriq+chemo boosts survival in first-line non-small cell lung cancer

pharmafile | October 22, 2018 | News story | Research and Development, Sales and Marketing Cancer, Roche, lung cancer NSCLC, pharma, tecentriq 

Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society for Medical Oncology (ESMO) 2018 Congress, with the Swiss pharma firm presenting new findings supporting the use of Tecentriq (atezolizumab) in combination with chemotherapy in the first-line treatment of previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC).

When paired with carboplatin and Abraxane chemo, Roche’s data showed that the combo allowed patients to live “significantly longer” lives, extending median overall survival by 18.6 months compared to 13.9 months for chemotherapy alone, and also improved progression-free survival rate by 7 months as opposed to 5.5. The safety profile of the drug was also found to be consistent with previous studies, with no new safety signals reported.

“Initial treatment with this Tecentriq-based combination provided a significant survival benefit for people with non-squamous non-small cell lung cancer, the most common form of lung cancer,” remarked Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “Lung cancer is a complex disease and this combination could offer a new potential treatment option. We will work with global health authorities to bring this regimen to people living with this disease as soon as possible.”

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

nerve-cell-2213009_960_720

Central nervous system cancer metastases – the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

The Gateway to Local Adoption Series

Latest content